We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,640.50 | 1,640.00 | 1,640.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.71 | 67.54B |
From Apr 2019 to Apr 2024
Ionis Pharmaceuticals Inc. said partner GlaxoSmithKline PLC has opted against initiating a phase-three study of a treatment for a rare, potentially fatal organ condition the companies have been co-developing.
The Carlsbad, Calif., drug developer's shares, down 43% this year, fell 17% to $29.36 in recent premarket trading.
The U.S. Food and Drug Administration in April placed a clinical hold on GlaxoSmithKline's phase-three study of Ionis-TTR as a potential treatment for patients with transthyretin amyloid cardiomyopathy, a condition in which the misfolded transthyretin protein accumulates in the cardiac muscle.
Ionis said that GlaxoSmithKline would consider options for transthyretin amyloid cardiomyopathy once additional clinical data are available from other studies that are under way.
Ionis is evaluating the treatment in patients with a hereditary version of transthyretin amyloidosis in continuing late-stage study, which the company said remains on track, with clinical data expected in the first half of next year.
Write to Tess Stynes at tess.stynes@wsj.com
(END) Dow Jones Newswires
May 26, 2016 09:35 ET (13:35 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
